Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial

European Heart Journal

Volumn 23, Issue 1, 2002, Pages 50-58

  Brown, Ruth E ^a   Henderson, R A ^b   Koster, D ^c   Hutton, J ^a   Simoons, M L ^d  

^a MEDTAP International Inc   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c Ingenix Inc   (United States)

^d Verhagen Uroloog   (Netherlands)

Author keywords

Cost effectiveness; Costs; Eptifibatide; Resources; Unstable angina

Indexed keywords

EPTIFIBATIDE; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; CORONARY ARTERY BYPASS; CORONARY DISEASE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; ENDPOINT DETERMINATION; EUROPE; FEMALE; HEALTH CARE COSTS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT ADMISSION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SYNDROME; TREATMENT OUTCOME;

EID: 0036403441     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2711     Document Type: Article

References (25)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of acute artery disease and the acute coronary syndromes (First of two parts). N Engl J Med 1992; 326: 242-50.
2. Harker LA. Strategies for inhibiting the effects of thrombin. Blood Coagul Fibrinolysis 1994; 5 (Suppl. 1): S47-S58.
3. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
4. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386-95.
5. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
6. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
7. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
8. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
9. The CAPTURE Investigators. Randomised, placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.
10. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422-8.
11. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
12. Harrington RA, Lincoff M, Berdan LG et al. Maintenance of clinical benefit at six-months in patients treated with platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event [Abstract no 1886]. Circulation 1998 Oct 27; Suppl. 1: 359.
13. Henderson R, Brown R. The costs of routine eptifibatide use in acute coronary syndromes in Western Europe: an economic substudy of the PURSUIT trial. Eur Heart J Supplements 1999; 1 (Suppl N): N35-N41.
14. Brown RE, McElwee N, Hutton J. Conducting cost analyses for international clinical trials (Abstr). International Society of Technology Assessment in Health Care. 14th Annual Meeting, 1998; 49.
15. Mark DB, Hlatky MA, Califf RM et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24.
16. Mark DB, Harrington RA, Lincoff AM et al. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST elevation acute coronary syndromes. Circulation 1999; 101: 366-71.
17. Akkerhuis KM, Deckers JW, Boersma E et al. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Cur Heart J 2000; 21: 371-81.
18. VandenBergh MF, van Hout BA, Maat AP et al. Cost effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. Infect Control Hosp Epidemiol 1996; 17: 789-92.
19. Laupacis A, Teen D, Detsky A et al. How attractive does a technology have to be to warrant adoption and utilisation? Can Med Assoc J 1992; 146: 473-81.
20. Mark DB. Medical economics in cardiovascular medicine, In: Topol EJ, ed. Textbook of Cardiovascular Medicine. New York, Lippincott-Raven, 1997; 1033-62.
21. Tengs TO, Adams ME, Pliskin JS et al. Five-hundred Life-saving Interventions and their Cost-effectiveness. Risk Analysis 1995; 15: 369-90.
22. Johannesson M, Jonsson B, Kjekshus J et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997; 336: 332-6.
23. Ashraf T, Hay JW, Pitt B et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996; 78: 409-14.
24. Krumholz HM, Pasternak RC, Weinstein MC et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327: 7-13.
25. Mushlin AI, Hall WJ, Zwanziger J et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 1998; 97: 2129-35.